In " Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how ...
MILAN — Is chronic lymphocytic leukemia (CLL) progression primarily driven by genetic mutations or by external cues from the tumor microenvironment? Despite major strides in targeted therapies, CLL ...
Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...
Faulty lipid regulation in CLL patients impairs T-cell function, affecting treatment outcomes and resistance to current therapies. Differences in lipid metabolism between CLL patients and healthy ...
Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...
Prompt recognition of autoimmune disease symptoms can help patients with chronic lymphocytic leukemia receive proper rheumatologic care. Immune dysregulation associated with chronic lymphocytic ...
Venetoclax demonstrated a 91% overall response rate and 44% complete response rate in octogenarians with CLL, comparable to younger cohorts. Common adverse events included neutropenia (37%) and grade ...
About 10 percent of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase (BTK) inhibitor drug ibrutinib because of disease progression during clinical ...
(RTTNews) - BeOne Medicines Ltd. (ONC) Thursday announced it presented new clinical data at the 2025 European Hematology Association or EHA Congress, highlighting the potential of its next-generation ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback